Achieve Life Sciences, Inc. Common Shares (ACHV) Stock
NASDAQ · ACHV
7.53
Fundamentals
Market cap
$775.88M
Price / Earnings ratio
-7.1x
Price / Sales ratio
N/A
Price / Book ratio
-54.9x
Return on assets
-112.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
NeutralACHVJuly 10, 2026
MarketBeatNeutral
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
ACHV

Reuters
US FDA declines to approve Achieve Life Sciences' smoking-cessation drug
NeutralACHVJune 22, 2026
ReutersNeutral
US FDA declines to approve Achieve Life Sciences' smoking-cessation drug
ACHV

MarketBeat
Achieve Life Sciences Q1 Earnings Call Highlights
NeutralACHVMay 12, 2026
MarketBeatNeutral
Achieve Life Sciences Q1 Earnings Call Highlights
ACHV

Stocktwits
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?
NeutralACHVApril 16, 2026
StocktwitsNeutral
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?
ACHV
Technicals
OscillatorsBuy5 Indicators
Moving AveragesNeutral12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
50M33M17M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-54.6M
Net incomeEarnings
No data available
% positive news of 5 articles
published over the past 14 days
Latest news

MarketBeat
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
NeutralACHVJuly 10, 2026
MarketBeatNeutral
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
ACHV

Reuters
US FDA declines to approve Achieve Life Sciences' smoking-cessation drug
NeutralACHVJune 22, 2026
ReutersNeutral
US FDA declines to approve Achieve Life Sciences' smoking-cessation drug
ACHV

MarketBeat
Achieve Life Sciences Q1 Earnings Call Highlights
NeutralACHVMay 12, 2026
MarketBeatNeutral
Achieve Life Sciences Q1 Earnings Call Highlights
ACHV

Stocktwits
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?
NeutralACHVApril 16, 2026
StocktwitsNeutral
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?
ACHV

Stocktwits
Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook
NeutralACHVDecember 30, 2025
StocktwitsNeutral
Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook
ACHV
About Achieve Life Sciences, Inc. Common Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees28
CEODr. Andrew D. Goldberg M.D.
IPO DateOct 13, 1995
HeadquartersBothell, WA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Erik Atkisson | Chief Legal Officer | 1972 |
| Dr. Andrew D. Goldberg M.D. | CEO, President & Director | 1982 |
| Mr. Mark K. Oki CPA | Chief Financial Officer | 1969 |
| Mr. Jerry Wan | VP of Finance & Principal Accounting Officer | 1982 |
| Dr. Mark L. Rubinstein M.D. | Chief Medical Officer | 1968 |
| Mr. Mark Zappia | Senior Vice President of Commercial | — |
| Mr. Ronald Dadino | Senior Vice President of Chemistry, Manufacturing & Controls and Supply Chain | — |
| Ms. Gloria Cosgrove | Senior Vice President of Global Quality | — |
| Ms. Nicole P. Jones | Vice President of Strategic Communications & Stakeholder Relations | — |
Fundamentals
Valuation
Market cap$775.88M
Price-to-sales ratioN/A
Price-to-book value-54.90
Price-earnings ratio-7.10
Return on Equity-194.00%
Return on SalesN/A
Return on Assets-112.00%
PEG ratio17.68
Earnings Per Share
Earnings Per Share$-1.53
Income Statement
Average volume1,600,648
EBITDA$-50.86M
1 year high (52w)$8.64
1 year low (52w)$2.62
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesNeutral12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$13.00
Est return
72.87%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.4 | -1.9 | -13.9 | +13.2 | ||||||||
| 2022 | -11.6 | -2.0 | +6.6 | -8.2 | +0.4 | -27.8 | +2.9 | -8.4 | -25.8 | -35.0 | +25.6 | -10.9 |
| 2023 | +92.1 | -3.8 | +41.4 | +15.7 | -27.8 | -19.7 | +11.1 | -11.9 | -17.0 | -5.4 | +35.6 | -29.5 |
| 2024 | +18.2 | -19.0 | +2.9 | -4.1 | +15.5 | -9.8 | +4.2 | -8.0 | +9.5 | -2.5 | -6.4 | -19.6 |
| 2025 | -11.4 | -5.8 | -6.3 | +3.6 | +46.1 | -42.1 | +17.6 | +16.9 | +7.9 | +65.2 | -4.7 | +6.9 |
| 2026 | -15.9 | +6.0 | -36.4 | +39.8 | +19.6 | +23.2 | +0.3 | +25.6 | -8.6 |



